SARS-CoV-2 Antibody Responses in Infection-Naive or Previously Infected Individuals After 1 and 2 Doses of the BNT162b2 Vaccine | Infectious Diseases | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

SARS-CoV-2 Antibody Responses in Infection-Naive or Previously Infected Individuals After 1 and 2 Doses of the BNT162b2 Vaccine

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME

The Pfizer/BioNTech (BNT162b2) SARS-CoV-2 mRNA vaccine demonstrated 95% efficacy after 2 doses during clinical trials.1 There are reports that individuals with previous SARS-CoV-2 infection elicit stronger antibody responses after 1 dose compared with individuals without prior infection.24 Consequently, individuals with a documented prior COVID-19 infection may be sufficiently protected from reinfection after a single mRNA vaccine dose, which could free up availability of millions of additional doses. We evaluated the SARS-CoV-2 spike immunoglobin (Ig) G antibody levels after 1 and 2 BNT162b2 doses in previously infected individuals compared with those without previous infection.

Sign in to take quiz and track your certificates

Buy This Activity

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: May 27, 2021.

Published: August 6, 2021. doi:10.1001/jamanetworkopen.2021.19741

Open Access: This is an open access article distributed under the terms of the CC-BY-NC-ND License. © 2021 Anderson M et al. JAMA Network Open.

Corresponding Author: James Moy, MD, Division of Allergy and Immunology, Department of Internal Medicine, Rush University Medical Center, 1725 W Harrison St, Ste 117, Chicago, IL 60612 (jmoy@rush.edu).

Author Contributions: Drs Anderson and Moy had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Anderson, Landay, Cloherty, Moy.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Anderson, Landay, Cloherty, Moy.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Anderson, Moy.

Obtained funding: Cloherty, Moy.

Administrative, technical, or material support: Anderson, Stec, Cloherty, Moy.

Supervision: Anderson, Landay, Cloherty, Moy.

Conflict of Interest Disclosures: None reported.

Funding/Support: This work was supported by Abbott Diagnostics Division Research and Development funding.

Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

References
1.
Polack  FP , Thomas  SJ , Kitchin  N ,  et al; C4591001 Clinical Trial Group.  Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine.   N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577PubMedGoogle ScholarCrossref
2.
Manisty  C , Otter  AD , Treibel  TA ,  et al.  Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals.   Lancet. 2021;397(10279):1057-1058. doi:10.1016/S0140-6736(21)00501-8PubMedGoogle ScholarCrossref
3.
Prendecki  M , Clarke  C , Brown  J ,  et al.  Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine.   Lancet. 2021;397(10280):1178-1181. doi:10.1016/S0140-6736(21)00502-XPubMedGoogle ScholarCrossref
4.
Bradley  T , Grundberg  E , Selvarangan  R ,  et al.  Antibody responses after a single dose of SARS-CoV-2 mRNA vaccine.   N Engl J Med. 2021;384(20):1959-1961. doi:10.1056/NEJMc2102051PubMedGoogle ScholarCrossref
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close